• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钌(II)和铂(II)配合物与具有生物活性的氨基黄酮配体表现出体外抗癌活性。

Ruthenium(II) and Platinum(II) Complexes with Biologically Active Aminoflavone Ligands Exhibit In Vitro Anticancer Activity.

机构信息

Departament of Bioinorganic Chemistry, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland.

出版信息

Int J Mol Sci. 2021 Jul 15;22(14):7568. doi: 10.3390/ijms22147568.

DOI:10.3390/ijms22147568
PMID:34299199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8306828/
Abstract

Continuing our studies on the mechanisms underlying the cytotoxicity of potential drugs, we have described several aspects of the in vitro anticancer activity of ruthenium(II) and platinum(II) complexes with bioactive, synthetic aminoflavone ligands. We examined the mechanism of proapoptotic activity of -dichlorobis(3-imino-2-methoxyflavanone)ruthenium(II), -dichlorobis(3-imino-2-ethoxyflavanone)ruthenium(II), and -dichlorobis(3-aminoflavone)platinum(II). Cisplatin was used as a reference compound. The cytotoxicity was investigated by MTT assay. The mechanism of proapoptotic activity of the tested compounds was investigated by evaluation of caspase-8 activity, cytometric analysis of annexin-V positive cells, and mitochondrial potential loss measurement. The results showed that ruthenium compounds break partially or completely the cisplatin resistance by activating the caspase 8-dependent apoptosis pathway and loss of mitochondrial membrane potential. Platinum compounds also have a cytostatic effect, but their action requires more exposure time. Potential mechanisms underlying drug resistance in the two pairs of cancer cell lines were investigated: total glutathione content, P-glycoprotein activity, and differences in the activity of DNA repair induced by nucleotide excision. Results showed that cisplatin-resistant cells have elevated glutathione levels relative to sensitive cells. Moreover, they indicated the mechanisms enabling cells to avoid apoptosis caused by DNA damage. Pg-P activity has no effect on the development of cisplatin resistance in the cell lines described.

摘要

我们继续研究潜在药物细胞毒性的作用机制,描述了具有生物活性的合成氨基黄酮配体的钌(II)和铂(II)配合物的体外抗癌活性的几个方面。我们研究了 -二氯二(3-亚氨基-2-甲氧基黄酮)钌(II)、-二氯二(3-亚氨基-2-乙氧基黄酮)钌(II)和 -二氯二(3-氨基黄酮)铂(II)的促凋亡活性的机制。顺铂被用作参考化合物。通过 MTT 测定法研究了细胞毒性。通过评估半胱天冬酶-8 活性、流式细胞术分析膜联蛋白-V 阳性细胞以及线粒体膜电位损失测量来研究测试化合物的促凋亡活性的机制。结果表明,钌化合物通过激活半胱天冬酶 8 依赖性凋亡途径和线粒体膜电位丧失部分或完全打破顺铂耐药性。铂化合物也具有细胞抑制作用,但它们的作用需要更长的暴露时间。在两对癌细胞系中研究了药物耐药性的潜在机制:总谷胱甘肽含量、P-糖蛋白活性以及核苷酸切除诱导的 DNA 修复活性的差异。结果表明,与敏感细胞相比,顺铂耐药细胞的谷胱甘肽水平升高。此外,这些结果表明了使细胞能够避免由 DNA 损伤引起的细胞凋亡的机制。Pg-P 活性对所描述的细胞系中顺铂耐药性的发展没有影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/f859400ee9c6/ijms-22-07568-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/80dabe2e11d1/ijms-22-07568-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/3e6209de79a1/ijms-22-07568-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/cea6f438e50f/ijms-22-07568-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/87f59e232270/ijms-22-07568-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/094e07c99891/ijms-22-07568-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/c56625057e0e/ijms-22-07568-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/a5011e04dff8/ijms-22-07568-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/bb791d03d70c/ijms-22-07568-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/f859400ee9c6/ijms-22-07568-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/80dabe2e11d1/ijms-22-07568-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/3e6209de79a1/ijms-22-07568-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/cea6f438e50f/ijms-22-07568-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/87f59e232270/ijms-22-07568-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/094e07c99891/ijms-22-07568-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/c56625057e0e/ijms-22-07568-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/a5011e04dff8/ijms-22-07568-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/bb791d03d70c/ijms-22-07568-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aaaa/8306828/f859400ee9c6/ijms-22-07568-g009.jpg

相似文献

1
Ruthenium(II) and Platinum(II) Complexes with Biologically Active Aminoflavone Ligands Exhibit In Vitro Anticancer Activity.钌(II)和铂(II)配合物与具有生物活性的氨基黄酮配体表现出体外抗癌活性。
Int J Mol Sci. 2021 Jul 15;22(14):7568. doi: 10.3390/ijms22147568.
2
Proapoptotic activity in vitro of two novel ruthenium(II) complexes with flavanone-based ligands that overcome cisplatin resistance in human bladder carcinoma cells.两种新型基于黄烷酮的钌(II)配合物在体外的促凋亡活性,可克服人膀胱癌细胞对顺铂的耐药性。
J Inorg Biochem. 2011 Apr;105(4):518-24. doi: 10.1016/j.jinorgbio.2010.12.013. Epub 2010 Dec 30.
3
Antitumor Activity of Pt(II), Ru(III) and Cu(II) Complexes.铂(II)、钌(III)和铜(II)配合物的抗肿瘤活性。
Molecules. 2020 Jul 31;25(15):3492. doi: 10.3390/molecules25153492.
4
Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.铂(IV)-氮氧自由基配合物作为克服 RT112 膀胱癌细胞顺铂耐药的可能候选物。
Arch Toxicol. 2017 Feb;91(2):785-797. doi: 10.1007/s00204-016-1754-3. Epub 2016 Jun 15.
5
Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms.高细胞毒性锇(II)化合物及其靶向卵巢癌细胞系并规避顺铂耐药机制的钌(II)类似物。
Int J Mol Sci. 2022 Apr 29;23(9):4976. doi: 10.3390/ijms23094976.
6
Synthesis, single-crystal and solution structure analysis and in vitro cytotoxic activity of two novel complexes of ruthenium(II) with in situ formed flavanone-based ligands.合成、单晶及溶液结构分析及新型钌(II)配合物的体外细胞毒性活性与原位形成的黄烷酮类配体。
Dalton Trans. 2010 Oct 28;39(40):9711-8. doi: 10.1039/c0dt00535e. Epub 2010 Sep 7.
7
Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.综述:旨在克服顺铂耐药性的铂配合物的发现与开发
J Inorg Biochem. 1999 Oct;77(1-2):111-5.
8
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.钌配合物的DNA结合模式及其与肿瘤细胞毒性的关系。
Drug Resist Updat. 2006 Jun;9(3):111-22. doi: 10.1016/j.drup.2006.05.002. Epub 2006 Jun 21.
9
Recent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of action.具有抑制和靶向作用机制的铂类化疗药物的最新进展。
J Inorg Biochem. 2020 Jun;207:111070. doi: 10.1016/j.jinorgbio.2020.111070. Epub 2020 Mar 23.
10
Fresh platinum complexes with promising antitumor activity.具有良好抗肿瘤活性的新型铂类配合物。
Anticancer Agents Med Chem. 2010 Jun;10(5):396-411. doi: 10.2174/1871520611009050396.

引用本文的文献

1
Multi-Pathway Study for Oxaliplatin Resistance Reduction.降低奥沙利铂耐药性的多途径研究
Curr Issues Mol Biol. 2025 Mar 4;47(3):172. doi: 10.3390/cimb47030172.
2
DNA Binding and Cleavage, Stopped-Flow Kinetic, Mechanistic, and Molecular Docking Studies of Cationic Ruthenium(II) Nitrosyl Complexes Containing "NS" Core.含“NS”核的阳离子钌(II)亚硝酰配合物的 DNA 结合与切割、稳态动力学、机理及分子对接研究
Molecules. 2023 Mar 28;28(7):3028. doi: 10.3390/molecules28073028.
3
Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs.

本文引用的文献

1
Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives.钌配合物作为抗癌剂:简要的历史和展望。
Drug Des Devel Ther. 2020 Dec 3;14:5375-5392. doi: 10.2147/DDDT.S275007. eCollection 2020.
2
Cisplatin: The first metal based anticancer drug.顺铂:第一种金属类抗癌药物。
Bioorg Chem. 2019 Jul;88:102925. doi: 10.1016/j.bioorg.2019.102925. Epub 2019 Apr 11.
3
Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433.
新型金属抗肿瘤药物的研究进展。
Molecules. 2023 Feb 18;28(4):1959. doi: 10.3390/molecules28041959.
4
Diversity-Oriented Synthesis: Amino Acetophenones as Building Blocks for the Synthesis of Natural Product Analogs.多样性导向合成:以氨基苯乙酮作为天然产物类似物合成的构建模块
Pharmaceuticals (Basel). 2021 Nov 5;14(11):1127. doi: 10.3390/ph14111127.
从肿瘤为中心的角度探讨过渡金属配合物和光动力疗法:TLD1433 开发中的挑战、机遇和亮点。
Chem Rev. 2019 Jan 23;119(2):797-828. doi: 10.1021/acs.chemrev.8b00211. Epub 2018 Oct 8.
4
Synthesis and Photobiological Activity of Ru(II) Dyads Derived from Pyrrole-2-carboxylate Thionoesters.源自吡咯-2-羧酸硫酯的钌(II)二元化合物的合成及光生物活性
Inorg Chem. 2017 Apr 3;56(7):4121-4132. doi: 10.1021/acs.inorgchem.7b00072. Epub 2017 Mar 16.
5
Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer.卵巢癌治疗中克服多药耐药性的新机制与新方法。
Biochim Biophys Acta. 2016 Dec;1866(2):266-275. doi: 10.1016/j.bbcan.2016.10.001. Epub 2016 Oct 4.
6
Exploring the Chemical Space of P-Glycoprotein Interacting Compounds.探索P-糖蛋白相互作用化合物的化学空间
Mini Rev Med Chem. 2017;17(14):1332-1345. doi: 10.2174/1389557516666160121120344.
7
trans-Platinum(II) complex of 3-aminoflavone - synthesis, X-ray crystal structure and biological activities in vitro.3-氨基黄酮的反式铂(II)配合物——合成、X射线晶体结构及体外生物活性
Dalton Trans. 2015 Jan 21;44(3):938-47. doi: 10.1039/c4dt01501k.
8
Ruthenium(II) complexes: DNA-binding, cytotoxicity, apoptosis, cellular localization, cell cycle arrest, reactive oxygen species, mitochondrial membrane potential and western blot analysis.钌(II)配合物:DNA结合、细胞毒性、细胞凋亡、细胞定位、细胞周期阻滞、活性氧、线粒体膜电位及蛋白质印迹分析
J Photochem Photobiol B. 2014 Nov;140:94-104. doi: 10.1016/j.jphotobiol.2014.07.011. Epub 2014 Jul 24.
9
Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?核苷酸切除修复:为什么它不能用于预测铂类化疗的反应?
Cancer Lett. 2014 May 1;346(2):163-71. doi: 10.1016/j.canlet.2014.01.005. Epub 2014 Jan 21.
10
[The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells].[miR-503对A549/DDP细胞顺铂耐药的逆转作用及分子机制]
Zhongguo Fei Ai Za Zhi. 2014 Jan;17(1):1-7. doi: 10.3779/j.issn.1009-3419.2014.01.01.